Challenges facing the development of cancer vaccines

Methods in Molecular Biology

Volumn 1139, Issue , 2014, Pages 543-553

  Fishman, Mayer ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Antigen presentation; Cancer vaccines; Tumor antigens

Indexed keywords

CA 19-9 ANTIGEN; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; INTERLEUKIN 13 RECEPTOR ALPHA2; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNE SYSTEM; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; TUMOR GROWTH; VACCINATION; ANIMAL; BIOSYNTHESIS; DRUG DEVELOPMENT; IMMUNOLOGY; REVIEW; TRANSLATIONAL RESEARCH;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DRUG DISCOVERY; HUMANS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84908282959     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0345-0_39     Document Type: Article

References (31)

1. Palucka K et al (2001) Dendritic cells and immunity against cancer. J Intern Med 269(1): 64-73.
2. Janikashvili N et al (2011) The dendritic cellregulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin Dev Immunol 430394. Epub 2011 Nov 3.
3. Gerlinger M et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10): 883-892.
4. Frankel TL et al (2010) Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J Immunol 184(11): 5988-5998.
5. Dalerba P et al (1998) High homogeneity of MAGE, BAGE, GAGE, tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: implications for protocol design of therapeutic antigen-specific vaccination strategies. Int J Cancer 77(2): 200-204.
6. Iwami K et al (2012) Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy 14(6): 733-742.
7. Shimato S et al (2008) Identification of a human leukocyte antigen-A24-restricted T-cell epitope derived from interleukin-13 receptor alpha2 chain, a glioma-associated antigen. J Neurosurg 109(1): 117-122.
8. Fishman M (2009) A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer. Expert Opin Biol Ther 9(12): 1565-1575.
9. Slota M et al (2011) ELISpot for measuring human immune responses to vaccines. Expert Rev Vaccines 10(3): 299-306.
10. Reiman JM et al (2007) Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol 17(4): 275-287.
11. Kim R et al (2007) Cancer immunoediting from immune surveillance to immune escape. Immunology 121(1): 1-14.
12. Tarp MA, Clausen H (2008) Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta 1780(3): 546-563.
13. Saldova R et al (2011) Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology 21(2): 195-205.
14. Schuster SJ et al (2011) Vaccination with patientspecific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 29(20): 2787-2794.
15. Wood C, C-100-12 RCC Study Group et al (2008) An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372(9633): 145-154.
16. Jocham D et al (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363(9409): 594-599.
17. Fishman M et al (2008) Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother 1: 72-80.
18. Kantoff PW et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5): 411-422.
19. Nagaraj S et al (2007) Dendritic cell-based fulllength survivin vaccine in treatment of experimental tumors. J Immunother 30(2): 169-179.
20. Pendino F et al (2006) Telomeres and telomerase: pharmacological targets for new anticancer strategies? Curr Cancer Drug Targets 6(2): 147-180.
21. Lane DP et al (2010) p53-based cancer therapy. Cold Spring Harb Perspect Biol 2(9): a001222, Epub May 12.
22. Burt C et al (2013) HLA-A,-B,-DR allele group frequencies in 7007 kidney transplant list patients in 27 UK centres. Int J Immunogenet 2013 Jun; 40(3): 209-215.
23. Mack SJ et al (2009) HLA-A,-B,-C, and-DRB1 allele and haplotype frequencies distinguish Eastern European Americans from the general European American population. Tissue Antigens 73(1): 17-32.
24. de Gruijl TD et al (2008) Whole-cell cancer vaccination: from autologous to allogeneic tumorand dendritic cell-based vaccines. Cancer Immunol Immunother 57(10): 1569-1577.
25. Le DT et al (2010) Cellular vaccine approaches. Cancer J 16(4): 304-310.
26. Facciabene A et al (2012) T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 72(9): 2162-2171.
27. So EY, Ouchi T (2010) The application of Toll like receptors for cancer therapy. Int J Biol Sci 6(7): 675-681.
28. Chiang CL et al (2011) Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol 30(2-3): 150-182.
29. Kusmartsev S, Gabrilovich DI (2002) Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 51(6): 293-298.
30. Gabrilovich DI et al (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12(4): 253-268.
31. Ruffell B et al (2012) Differential macrophage programming in the tumor microenvironment. Trends Immunol 33(3): 119-126, Epub 2012 Jan 23.